OncoMatch/Clinical Trials/NCT07089641
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Is NCT07089641 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies EGFR Inhibitor ERAS-801 for idh wildtype glioblastoma.
Treatment: EGFR Inhibitor ERAS-801 — This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or astrocytoma that can be removed by surgery (resectable) and that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). Glioblastoma is the most common brain cancer in adults and survival rates remain poor despite treatment including surgery, radiation and chemotherapy. EGFR is a protein found on the surface of some cells, to which epidermal growth factor binds, causing the cells to divide. It is found at abnormally high levels on the surface of many types of tumor cells, so these cells may divide excessively in the presence of epidermal growth factor. ERAS-801, an EGFR inhibitor that can penetrate the central nervous system, binds to the tumor cells that express EGFR and may help shrink or slow the growth of the tumor cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: EGFR amplification
Required: EGFR mutation
Required: IDH1 wild-type
Disease stage
Required: Stage IV (WHO)
Grade: IV (WHO)
WHO grade IV glioblastoma/astrocytoma, which is progressive or recurrent following radiation therapy +/- chemotherapy
Prior therapy
Must have received: radiation therapy
progressive or recurrent following radiation therapy +/- chemotherapy
Cannot have received: EGFR inhibitor
Participants with prior therapy with EGFR inhibitors are ineligible
Lab requirements
Blood counts
ANC ≥ 1000/uL; Platelets ≥ 100,000/uL; Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L (without erythropoietin dependency and without pRBC transfusion within last 2 weeks)
Kidney function
Creatinine ≤ 1 x ULN OR creatinine clearance ≥ 30 mL/min
Liver function
Total bilirubin ≤ 1.5 x ULN unless with Gilbert's syndrome; AST and ALT ≤ 3 x ULN
Cardiac function
LVEF within normal institutional limits within 21 days of starting treatment; 12-lead ECG with QTcF < 450 msec
ANC ≥ 1000/uL; Platelets ≥ 100,000/uL; Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L (without erythropoietin dependency and without pRBC transfusion within last 2 weeks); Creatinine ≤ 1 x ULN OR creatinine clearance ≥ 30 mL/min; Total bilirubin ≤ 1.5 x ULN unless with Gilbert's syndrome; AST and ALT ≤ 3 x ULN; LVEF within normal institutional limits within 21 days of starting treatment; 12-lead ECG with QTcF < 450 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify